| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Gisbert JP | |
| Vergara M | |||
| Catalán M | |||
| Calvet X | |||
| P2860 | cites work | Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 |
| Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen | Q28164178 | ||
| Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use | Q28193290 | ||
| Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial | Q28216474 | ||
| A method for assessing the quality of a randomized control trial | Q34283065 | ||
| Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis | Q34520598 | ||
| Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking | Q34737659 | ||
| Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial | Q35594930 | ||
| Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis | Q44261800 | ||
| Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial | Q44364929 | ||
| Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti‐inflammatory drug users – a randomized trial | Q44611995 | ||
| Estrategia clínica para la prevención de los efectos adversos sobre el tracto digestivo de los antiinflamatorios no esteroideos | Q58912980 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Helicobacter pylori | Q180556 |
| meta-analysis | Q815382 | ||
| prevention | Q1717246 | ||
| Helicobacter pylori infectious disease | Q4497153 | ||
| P304 | page(s) | 1411-1418 | |
| P577 | publication date | 2005-06-01 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users | |
| P478 | volume | 21 |
| Q38113105 | 3rd Brazilian Consensus on Helicobacter pylori. |
| Q40378087 | ACG Clinical Guideline: Treatment of Helicobacter pylori Infection |
| Q34645482 | American College of Gastroenterology guideline on the management of Helicobacter pylori infection |
| Q34408985 | Assessing the risks and benefits of treating Helicobacter pylori infection. |
| Q37666625 | Assessment of the environmental risk factors for a gastric ulcer in northern Ghana |
| Q64101672 | Association of Diverticulitis with Prolonged Spondyloarthritis: An Analysis of the ASAS-COMOSPA International Cohort |
| Q36951930 | Bleeding peptic ulcer in the elderly: risk factors and prevention strategies |
| Q39593562 | COX-2 Gene Promoter Methylation in Patients Infected with Helicobacter Pylori |
| Q34448307 | Clinical Rationale for Confirmation Testing After Treatment of Helicobacter pylori Infection: Implications of Rising Antibiotic Resistance |
| Q38211000 | Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence. |
| Q37358250 | Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations |
| Q33698340 | Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale |
| Q33624655 | Contemporary Diagnostic Strategies for the Detection of Helicobacter pylori Infection |
| Q45807693 | Continuous proton pump inhibitor treatment decreases upper gastrointestinal bleeding and related death in rural area in Japan |
| Q55071130 | Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits. |
| Q36715136 | Cost Effectiveness Associated with Helicobacter pylori Screening and Eradication in Patients Taking Nonsteroidal Anti-Inflammatory Drugs and/or Aspirin |
| Q38578616 | Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents |
| Q24674636 | Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report |
| Q46620474 | Effect of a community screening for Helicobacter pylori: a 5-Yr follow-up study |
| Q42371575 | Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression |
| Q34581560 | Eradication of Helicobacter pylori for the prevention of peptic ulcer rebleeding. |
| Q34408895 | Eradication of helicobacter pylori to prevent gastroduodenal diseases: hitting more than one bird with the same stone |
| Q40790399 | Evidence-based clinical practice guidelines for peptic ulcer disease 2015. |
| Q38072783 | Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection |
| Q27026351 | Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies |
| Q38206548 | Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition |
| Q40100019 | H. pylori Management in ASEAN: the Bangkok Consensus Report. |
| Q89589595 | Helicobacter Pylori Infection |
| Q83196305 | Helicobacter pylori and NSAID-induced gastric ulcer in a Japanese population |
| Q39242036 | Helicobacter pylori and nonmalignant diseases |
| Q43821335 | Helicobacter pylori and risk of upper gastrointestinal bleeding among users of selective serotonin reuptake inhibitors. |
| Q38132278 | Helicobacter pylori infection in Europe: current perspectives |
| Q35555697 | Helicobacter pylori infection in bleeding peptic ulcer patients after non-steroidal antiinflammatory drug consumption. |
| Q45899590 | Helicobacter pylori management in non-steroidal anti-inflammatory drug therapy patients in primary care. |
| Q61521922 | Helicobacter pylori management in primary care |
| Q61962966 | Helicobacter pylori y gastroprotección |
| Q37346038 | Helicobacter pylori: testing and treatment |
| Q90011065 | Hellenic consensus on Helicobacter pylori infection |
| Q33417972 | Hematologic manifestations of Helicobacter pylori infection |
| Q52646227 | Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. |
| Q42949209 | Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan |
| Q34663572 | Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights |
| Q28219634 | Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases |
| Q64233060 | International Consensus on Guiding Recommendations for Management of Patients with Nonsteroidal Antiinflammatory Drugs Induced Gastropathy-ICON-G |
| Q79977758 | Is perforated marginal ulcer after the surgery of gastroduodenal ulcer associated with inadequate treatment for Helicobacter pylori eradication? |
| Q26799430 | Kyoto global consensus report on Helicobacter pylori gastritis |
| Q35989849 | Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled tria |
| Q37246006 | Low-dose aspirin-induced gastrointestinal diseases: past, present, and future |
| Q34449825 | Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis. |
| Q40221146 | Management of Helicobacter Pylori in the United States: Results from a national survey of gastroenterology physicians. |
| Q38699305 | Management of NSAID-associated peptic ulcer disease. |
| Q37800342 | NSAID-induced gastrointestinal and cardiovascular injury |
| Q43274525 | NSAIDs and the gastrointestinal tract |
| Q57169425 | Non-Steroidal Anti-Inflammatory Drug-Induced Gastro-Duodenal Toxicity |
| Q38974392 | Nonsteroidal Anti-Inflammatory Drug-Induced Gastroduodenal Bleeding: Risk Factors and Prevention Strategies |
| Q84409245 | Peptic ulcer disease |
| Q28194844 | Peptic ulcer disease today |
| Q37587472 | Perforated peptic ulcer - an update |
| Q33960344 | Population-based strategies for Helicobacter pylori-associated disease management: a Japanese perspective. |
| Q38848225 | Potential role of probiotics in the management of gastric ulcer |
| Q98612889 | Practice Advisory on the Appropriate Use of NSAIDs in Primary Care |
| Q41744470 | Prevention and Treatment of NSAID Gastropathy |
| Q40087299 | Prevention of Indomethacin-Induced Gastric Mucosal Injury in Helicobacter pylori-Negative Healthy Volunteers: A Comparison Study Rebamipide vs Famotidine |
| Q37893966 | Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors |
| Q34655792 | Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance |
| Q91796561 | Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved |
| Q38001074 | Risk and preventive factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive review |
| Q35026472 | Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin |
| Q82615517 | Role of Helicobacter pylori infection in gastroduodenal damage in patients starting NSAID therapy: 4 Months follow-up study |
| Q30629677 | Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks |
| Q38541866 | Safety and efficacy of paracetamol and NSAIDs in osteoarthritis: which drug to recommend? |
| Q34550255 | The risk of upper gastrointestinal bleeding in patients treated with hemodialysis: a population-based cohort study |
| Q38032319 | Therapeutic management of recurrent peptic ulcer disease |
| Q45974314 | Think before or sink after: choosing an appropriate NSAID by balancing gastrointestinal and cardiovascular risks. |
| Q33372344 | Treatment of Helicobacter pylori infection |
| Q94340226 | UEG Week 2016 Poster Presentations |
| Q41005318 | Upper Gastrointestinal Bleeding in Children: The Role of Helicobacter pylori Infection and Non-steroidal Anti-inflammatory Drug Use. |
| Q38041462 | Upper gastrointestinal bleeding associated with NSAIDs, other drugs and interactions: a nested case-control study in a new general practice database. |
| Q80447654 | [Helicobacter pylori] |
| Q79520438 | [Recommendations for the management of Helicobacter pylori infection according to Maastricht 3 guidelines] |
Search more.